ChartMill assigns a Buy % Consensus number of 80% to CLRB. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-05-14 | Maxim Group | Downgrade | Buy -> Hold |
| 2024-12-11 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-11-19 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-10-11 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-28 | Roth MKM | Maintains | Buy -> Buy |
| 2024-03-28 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-04 | Roth MKM | Reiterate | Buy -> Buy |
| 2022-11-04 | HC Wainwright & Co. | Maintains | Buy |
10 analysts have analysed CLRB and the average price target is 47.94 USD. This implies a price increase of 1224.31% is expected in the next year compared to the current price of 3.62.
The consensus rating for CELLECTAR BIOSCIENCES INC (CLRB) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering CELLECTAR BIOSCIENCES INC (CLRB) is 10.